No Data
No Data
What You Need To Know About The Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Analyst Downgrade Today
Revenue Downgrade: Here's What Analysts Forecast For Sangamo Therapeutics, Inc. (NASDAQ:SGMO)
Today is shaping up negative for Sangamo Therapeutics, Inc. (NASDAQ:SGMO) shareholders, with the analysts delivering a substantial negative revision to this year's forecasts. There was a fairly drac
Sangamo Therapeutics Shares Drop 15% After $24M Offering Prices
By Chris Wack Sangamo Therapeutics shares were down 14% to 83 cents after the company entered a securities purchase agreement with institutional investors for the purchase and sale of 24.8 million sh
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced that it has entered into a securities purchase agreement with institutional investors, providing for the purchase and sale of an
Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform
H.C. Wainwright initiated coverage on Voyager Therapeutics Inc (NASDAQ:VYGR), noting a growing franchise of novel, highly-differentiated adeno-associated virus (AAV)-based TRACER capsids with the pote
HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Raises Price Target to $5
HC Wainwright & Co. analyst Patrick Trucchio reiterates Sangamo Therapeutics with a Buy and raises the price target from $3 to $5.
No Data